Genetic Stability of Driver Alterations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type and Their Relapses: A Rationale for the Use of Molecular-Based Methods for More Effective Disease Monitoring
Authors:
- Anne M. R. SchraderASAnne M. R. Schrader
- Ruben A. L. de GroenRGRuben A. L. de Groen
- Rein WillemzeRWRein Willemze
- Patty M. JansenPJPatty M. Jansen
- Koen D. QuintKQKoen D. Quint
- Arjen H. G. ClevenACArjen H. G. Cleven
- Tom van WezelTWTom van Wezel
- Ronald van EijkRERonald van Eijk
- Dina RuanoDRDina Ruano
- J. Hendrik VeelkenJVJ. Hendrik Veelken
- Cornelis P. TensenCTCornelis P. Tensen
- Karen J. NeelisKNKaren J. Neelis
Open Access
Abstract
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is a rare, aggressive cutaneous lymphoma with a 5-year disease-specific survival of only ~55%. Despite high response rates to initial immune-polychemotherapy, most patients experience a disease relapse. The genetic evolution of primary and relapsed/refractory disease has only scarcely been studied in PCDLBCL-LT patients. Therefore, in this retrospective cohort study, 73 primary/pre-treatment and relapsed/refractory biopsies of 57 patients with PCDLBCL-LT were molecularly characterized with triple FISH and targeted next-generation sequencing for 52 B-cell-lymphoma-relevant genes, including paired analysis in 16 patients. In this cohort, 95% of patients harboured at least one of the three main driver alterations (mutations in MYD88/CD79B and/or CDKN2A-loss). In relapsed/refractory PCDLBCL-LT, these oncogenic aberrations were persistently present, demonstrating genetic stability over time. Novel alterations in relapsed disease affected mostly CDKN2A, MYC, and PIM1. Regarding survival, only MYC rearrangements and HIST1H1E mutations were statistically significantly associated with an inferior outcome. The stable presence of one or more of the three main driver alterations (mutated MYD88/CD79B and/or CDKN2A-loss) is promising for targeted therapies addressing these alterations and serves as a rationale for molecular-based disease monitoring, improving response evaluation and early identification and intervention of disease relapses in these poor-prognostic PCDLBCL-LT patients.Keywords
Funding Information
- Stichting Fonds Oncologie Holland
This publication has 30 references indexed in Scilit:
- Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel SequencingJournal of Investigative Dermatology, 2017
- Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79Haematologica, 2017
- Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNAScience Translational Medicine, 2016
- Targetable genetic features of primary testicular and primary central nervous system lymphomasBlood, 2016
- Excellent Outcome of Immunomodulation or Bruton's Tyrosine Kinase Inhibition in Highly Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg TypeRare Tumors, 2015
- High Frequency and Clinical Prognostic Value of MYD88 L265P Mutation in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-TypeJAMA Dermatology, 2014
- Recurrent targets of aberrant somatic hypermutation in lymphomaOncotarget, 2012
- Fine-Mapping Chromosomal Loss at 9p21: Correlation with Prognosis in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg TypeJournal of Investigative Dermatology, 2009
- Reclassification of 300 Primary Cutaneous B-Cell Lymphomas According to the New WHO–EORTC Classification for Cutaneous Lymphomas: Comparison With Previous Classifications and Identification of Prognostic MarkersJournal of Clinical Oncology, 2007
- Primary cutaneous follicle center lymphoma and primary cutaneous large B-cell lymphoma, leg type, are both targeted by aberrant somatic hypermutation but demonstrate differential expression of AIDBlood, 2006